1999 - Member of the National Academy of Medicine (NAM)
1973 - Fellow of John Simon Guggenheim Memorial Foundation
His Cell biology study frequently draws parallels with other fields, such as Protein kinase A. Michael L. Shelanski integrates Protein kinase A and Cyclic adenosine monophosphate in his studies. Michael L. Shelanski performs multidisciplinary study in Cyclic adenosine monophosphate and Forskolin in his work. His Receptor research extends to the thematically linked field of Forskolin. His work on Receptor is being expanded to include thematically relevant topics such as Long-term potentiation. In his articles, he combines various disciplines, including Long-term potentiation and CREB. Michael L. Shelanski integrates CREB with Gene in his research. Michael L. Shelanski incorporates Gene and Function (biology) in his studies. His research on Function (biology) frequently connects to adjacent areas such as Cell biology.
His Biochemistry study frequently draws connections between adjacent fields such as Peptide. Much of his study explores Peptide relationship to Biochemistry. Cell biology and SPINE (molecular biology) are frequently intertwined in his study. As part of his studies on SPINE (molecular biology), Michael L. Shelanski frequently links adjacent subjects like Cell biology. In his research, he performs multidisciplinary study on Neuroscience and Pharmacology. Pharmacology and Neuroscience are two areas of study in which he engages in interdisciplinary research. Many of his studies on Disease involve topics that are commonly interrelated, such as Amyloid precursor protein. In his research, Michael L. Shelanski performs multidisciplinary study on Amyloid precursor protein and Alzheimer's disease. In his research, Michael L. Shelanski undertakes multidisciplinary study on Alzheimer's disease and Presenilin.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Microtubule Assembly in the Absence of Added Nucleotides
Michael L. Shelanski;Felicia Gaskin;Charles R. Cantor.
Proceedings of the National Academy of Sciences of the United States of America (1973)
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.
Adam C. Naj;Gyungah Jun;Gary W. Beecham;Li-San Wang.
Nature Genetics (2011)
Primary care outcomes in patients treated by nurse practitioners or physicians: a randomized trial.
Mary O. Mundinger;Robert L. Kane;Elizabeth R. Lenz;Annette M. Totten.
Primary age-related tauopathy (PART): a common pathology associated with human aging
John F. Crary;John Q. Trojanowski;Julie A. Schneider;Jose F. Abisambra.
Acta Neuropathologica (2014)
Synergistic Effects of Traumatic Head Injury and Apolipoprotein-epsilon4 in Patients With Alzheimer's Disease
R. Mayeux;R. Ottman;G. Maestre;C. Ngai.
Astroglia in CNS injury
Mary E. Hatten;Ronald K. H. Liem;Michael L. Shelanski;Corol A. Mason.
Amyloid β-peptide inhibition of the PKA/CREB pathway and long-term potentiation: Reversibility by drugs that enhance cAMP signaling
Ottavio V. Vitolo;Antonino Sant'Angelo;Vincenzo Costanzo;Fortunato Battaglia.
Proceedings of the National Academy of Sciences of the United States of America (2002)
Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment
Bing Gong;Ottavio V. Vitolo;Fabrizio Trinchese;Shumin Liu.
Journal of Clinical Investigation (2004)
The National Alzheimer's Coordinating Center (NACC) database: the Uniform Data Set.
Duane L. Beekly;Erin M. Ramos;William W. Lee;Woodrow D. Deitrich.
Alzheimer Disease & Associated Disorders (2007)
Sequence of a cDNA clone encoding mouse glial fibrillary acidic protein: structural conservation of intermediate filaments
Sally A. Lewis;Joanna M. Balcarek;Veronica Krek;Michael Shelanski.
Proceedings of the National Academy of Sciences of the United States of America (1984)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: